Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or basal insulin. We extracted data from citation dat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/11/9/639 |
| _version_ | 1829091916359139328 |
|---|---|
| author | Shinje Moon Hye-Soo Chung Yoon-Jung Kim Jae-Myung Yu Woo-Ju Jeong Jiwon Park Chang-Myung Oh |
| author_facet | Shinje Moon Hye-Soo Chung Yoon-Jung Kim Jae-Myung Yu Woo-Ju Jeong Jiwon Park Chang-Myung Oh |
| author_sort | Shinje Moon |
| collection | DOAJ |
| description | Insulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or basal insulin. We extracted data from citation databases, including PubMed, EMBASE, and the Cochrane Library, since inception to 2021. We calculated the mean differences for hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), self-measured mean glucose, and postprandial glucose (PPG) and odds ratios for confirmed hypoglycemia events. Compared with twice-daily conventional premixed insulin, twice-daily IDegAsp showed a similar effect on changes in HbA1c, but it significantly reduced FPG and self-measured mean glucose levels. Furthermore, compared to once-daily basal insulin, once-daily IDegAsp had a similar effect on changes in HbA1c, but it significantly reduced self-measured mean glucose and PPG levels. The risk of overall confirmed hypoglycemia was similar between treatments; however, the risk of nocturnal hypoglycemia events was significantly lower with IDegAsp than with conventional premixed insulin and basal insulin. Thus, IDegAsp was more effective than conventional premixed insulin and basal insulin at reducing blood glucose with fewer nocturnal hypoglycemia events. |
| first_indexed | 2024-03-10T07:26:59Z |
| format | Article |
| id | doaj.art-6941b4db95024285a2feddd38a1a4e5e |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-10T07:26:59Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-6941b4db95024285a2feddd38a1a4e5e2023-11-22T14:12:11ZengMDPI AGMetabolites2218-19892021-09-0111963910.3390/metabo11090639Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-AnalysisShinje Moon0Hye-Soo Chung1Yoon-Jung Kim2Jae-Myung Yu3Woo-Ju Jeong4Jiwon Park5Chang-Myung Oh6Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24252, KoreaDepartment of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24252, KoreaDepartment of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24252, KoreaDepartment of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24252, KoreaDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, KoreaDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, KoreaDepartment of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, KoreaInsulin degludec/insulin aspart (IDegAsp) is a novel co-formulation of 70% insulin degludec and 30% insulin aspart. The present meta-analysis was conducted to assess the efficacy and safety of IDegAsp compared with a conventional premixed insulin or basal insulin. We extracted data from citation databases, including PubMed, EMBASE, and the Cochrane Library, since inception to 2021. We calculated the mean differences for hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), self-measured mean glucose, and postprandial glucose (PPG) and odds ratios for confirmed hypoglycemia events. Compared with twice-daily conventional premixed insulin, twice-daily IDegAsp showed a similar effect on changes in HbA1c, but it significantly reduced FPG and self-measured mean glucose levels. Furthermore, compared to once-daily basal insulin, once-daily IDegAsp had a similar effect on changes in HbA1c, but it significantly reduced self-measured mean glucose and PPG levels. The risk of overall confirmed hypoglycemia was similar between treatments; however, the risk of nocturnal hypoglycemia events was significantly lower with IDegAsp than with conventional premixed insulin and basal insulin. Thus, IDegAsp was more effective than conventional premixed insulin and basal insulin at reducing blood glucose with fewer nocturnal hypoglycemia events.https://www.mdpi.com/2218-1989/11/9/639type 2 diabetesinsulin degludecinsulin aspartpremixed insulinglycemic controlhypoglycemia |
| spellingShingle | Shinje Moon Hye-Soo Chung Yoon-Jung Kim Jae-Myung Yu Woo-Ju Jeong Jiwon Park Chang-Myung Oh Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis Metabolites type 2 diabetes insulin degludec insulin aspart premixed insulin glycemic control hypoglycemia |
| title | Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis |
| title_full | Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis |
| title_fullStr | Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis |
| title_short | Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis |
| title_sort | efficacy and safety of insulin degludec insulin aspart compared with a conventional premixed insulin or basal insulin a meta analysis |
| topic | type 2 diabetes insulin degludec insulin aspart premixed insulin glycemic control hypoglycemia |
| url | https://www.mdpi.com/2218-1989/11/9/639 |
| work_keys_str_mv | AT shinjemoon efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT hyesoochung efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT yoonjungkim efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT jaemyungyu efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT woojujeong efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT jiwonpark efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis AT changmyungoh efficacyandsafetyofinsulindegludecinsulinaspartcomparedwithaconventionalpremixedinsulinorbasalinsulinametaanalysis |